Search:

Type: Posts; User: gpawelski; Keyword(s):

Page 1 of 3 1 2 3

Search: Search took 0.13 seconds.

  1. The robust performance of drugs that target ALK...

    The robust performance of drugs that target ALK and EGFR has made testing for mutations in these genes routine. But as the cost of sequencing plummets, some clinicians believe that it makes more...
  2. Genomic analysis has proven to be harder to realize than expected

    Therapies targeted at the specific genetics of a patient's lung cancer have proved harder to realize than expected.

    Ramaswamy Govindan vividly remembers the first time he treated his patients with...
  3. Employing multi-dimensional analyses of both genomic and phenotypic platforms

    Robert A. Nagourney, M.D.

    Oncologists confront numerous hurdles as they attempt to apply the new cancer prognostic and predictive tests. Among them are the complexities of gene arrays that...
  4. Quest for Targeted Therapeutic 'Cocktails' Hits Roadblocks

    Mark Pegram, M.D.

    The use of cutting-edge technology and bioinformatics to inform clinical decision-making in oncology is still a ways off, according to Mark Pegram, MD, the Susy Yuan-Huey Hung...
  5. MCED in glioblastoma patients measures favorable responses to Avastin

    MCED explains why glioblastoma (the most common primary brain tumor) patients who have favorable responses to bevacizumab (Avastin) develop early calcifications in the tumor bed while glioblastoma...
  6. Predicting tumor response to anti-angiogenic drugs

    Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous...
  7. Glioblastoma survival improved following FDA approval of Avastin

    A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than...
  8. Is tumor calcification a good thing or a bad thing?

    It's neither. It gives a much better understanding of what happens when Avastin is used. In pharmacology, the term agonist-antagonist is used to refer to a drug which exhibits some properties of an...
  9. Cell culture detection of microvascular cell death

    J Intern Med. 2008 Sep;264(3):275-87.

    Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood.

    Weisenthal LM, Patel N, Rueff-Weisenthal...
  10. Cyclin-dependent kinases as therapeutic targets

    Cyclin-dependent kinases as therapeutic targets: Examination of palbociclib (PD 0332991) and flavopiridol in human tumor primary culture microspheroids.

    Author(s): Robert Alan Nagourney, Eknath A....
  11. Replies
    2
    Views
    7,293

    What's all involved with inflammatory breast cancer?

    Beth Overmoyer, M.D.
    Director
    Inflammatory Breast Cancer Program
    Dana Farber Cancer Institute

    The treatment of inflammatory breast cancer requires a “tri-modality” approach, meaning that all...
  12. Replies
    2
    Views
    7,293

    Vitamin D to Tumors for Possible Inflammatory Breast Cancer Treatment

    The shortened daylight of a Maine winter may make for long, dark nights -- but it has shone a light on a novel experimental approach to fighting inflammatory breast cancer (IBC), an especially deadly...
  13. Replies
    2
    Views
    7,293

    Inflammatory Breast Cancer

    Silvana Martino, M.D.
    Director of Breast Cancer Research and Education
    The Angeles Clinic Foundation

    This is a particularly aggressive form of breast cancer. Its name is derived from the fact...
  14. Palbociclib Extends PFS in ER-positive/HER2-negative Breast Cancer

    Treatment with palbociclib combined with letrozole resulted in significantly improved progression-free survival (PFS) compared with letrozole alone in patients with hormone receptor-positive...
  15. The cyclin-dependent kinase inhibitors

    These kinase inhibitors can work across various types of cancer, but often only extend life by around three to six months. However, researchers believe they can unlock the true potential of these...
  16. Bemaciclib Seems Safe, Effective for Advanced Disease

    In an early trial, an experimental breast cancer drug stopped disease growth and shrank tumors by more than 30 percent in some patients.

    The pill, bemaciclib, was safe and well-tolerated by women...
  17. Palbociclib stymies cancer progression but falls short on survival

    Palbociclib doubled the average amount of progression-free survival (PFS) time among patients with advanced breast cancer. But in the first detailed glimpse of its impact on overall survival (OS) - a...
  18. Cancer is not a genomic disorder, but a metabolic disorder

    Robert A. Nagourney, M.D.

    A study conducted by Canadian investigators and reported in the September 1, 2013 issue of the Journal of Clinical Oncology examined the impact of Metformin use on...
  19. Triple Negative Breast Cancer: Worse or Just Different?

    Robert A. Nagourney, M.D.

    The term “triple negative breast cancer” (TNBC) is applied to a subtype of breast cancers that do not express the estrogen or progesterone receptors. Nor do they...
  20. Deferred use of Avastin not associated with diminished efficacy

    Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

    David E. Piccioni, Julia Selfridge, Reema R. Mody, Reshmi Chowdhury, Sichen Li, Shadi Lalezari,...
  21. Cancer cells get energy and raw materials for growth from glucose

    Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

    Published...
  22. A potential new treatment option for patients with brain cancer

    A novel drug for patients with brain cancer, 2B3-101, has shown preliminary positive results. The Dutch biotech to-BBB has developed Glutathione PEGylated liposomal doxorubicin (2B3-101) and...
  23. Is It Ethical to Deny Cancer Patients Functional Analyses?

    Robert A. Nagourney, M.D.

    The ethical standards that govern human experimentation have become an important topic of discussion. Clinical trials are conducted to resolve medical questions while...
  24. Scientists challenge the genetic interpretation of biology

    A proposal for reformulating the foundations of biology, based on the 2nd law of thermodynamics and which is in sharp contrast to the prevailing genetic view, is published in the Journal of the Royal...
  25. Pharmacogenomics can be defined as the study of...

    Pharmacogenomics can be defined as the study of how a person’s genetic makeup determines response to a drug. Although any number of labs and techniques can detect mutant genes, this area of...
  26. First FDA Authorization for Next-Generation Sequencer

    Francis S. Collins, M.D., Ph.D., and Margaret A. Hamburg, M.D.
    N Engl J Med 2013; 369:2369-2371December 19, 2013DOI: 10.1056/NEJMp1314561

    Article

    This year marks 60 years since James Watson...
  27. Genome-wide sequencing in cancer: not ready for prime time

    (Reuters Health) - Routine genome-wide screening of cancers is likely a long way off, a new paper says.

    The technology, known as next-generation sequencing, promises to revolutionize doctors'...
  28. Dr. Weisenthal Replies to ASCO Post

    Replies to comments regarding personalized cancer treatment, as published in the December 15, 2013 "ASCO Post" (American Society of Clinical Oncology publication).

    By Larry Weisenthal, MD...
  29. Avastin Misses Mark Again in Breast Cancer?

    The addition of bevacizumab (Avastin) to standard adjuvant therapy for HER2-positive breast cancer failed to improve invasive disease-free survival (iDFS) in a randomized clinical trial.

    Patients...
  30. BEATRICE: Adjuvant chemotherapy/Avastin (Bevacizumab)

    The first presentation of the BEATRICE trial, evaluating adjuvant Avastin with a physician’s choice taxane- and/or anthracycline-based regimen in patients with triple-negative disease, was at the...
  31. Does BEATRICE Spell the End of Avastin (bevacizumab) in Breast Cancer?

    Direct anti-tumor and anti-vascular effects were studied of Tykerb, Nexavar and Avastin in fresh biopsy specimens of breast cancer and presented at the American Society of Clinical Oncology Breast...
  32. Avastin (bevacizumab) Fails in Advanced, HR-Positive Breast Cancer?

    All women in the BEATRICE trial with triple negative early breast cancer received chemotherapy. One half were also given Avastin (bevacizumab). There was no difference in outcome with or without...
  33. pCR Arrives as a Standard Measure in Breast Cancer

    A new study strengthens the evidence that pathological complete response (pCR) is a good surrogate marker of longer-term efficacy in the neoadjuvant drug treatment of breast cancer.

    pCR, which is...
  34. Cancer Patients Who Get Better, Get Better

    Robert A. Nagourny, M.D.
    Rational Therapeutics

    A study published in the October 20 Journal of Clinical Oncology (Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal...
  35. Analyte-based Tests vs Functional Platforms

    Robert A. Nagourney, M.D.
    Medical and Laboratory Director
    Rational Therapeutics, Inc.
    Long Beach, California

    I recently had an interesting conversation with a physician regarding her patient...
  36. A Focus on Triple Negative Disease

    As our understanding of breast cancer biology continues to advance, this disease has come to be understood as many different diseases. Original categorizations based on histology lead to lobular...
  37. Avastin + Tykerb first clinically-exploitable antivascular drug combination?

    Direct anti-tumor and anti-vascular effects were studied of Tykerb, Nexavar and Avastin in fresh biopsy specimens of breast cancer and presented at the American Society of Clinical Oncology Breast...
  38. Triple Negative Breast Cancer (TNBC)

    A study was presented at the 2009 American Society of Clinical Onocology (ASCO) breast cancer symposium in San Francisco about progress in drug selection through the use of cell-based functional...
  39. Platinum-Based Treatment of Triple-Negative Breast Cancer

    Larry Weisenthal, MD, PhD

    The last issue of The ASCO Post reports encouraging results with platinum-based treatment of triple-negative breast cancer (September 15, 2013).

    We predicted these...
  40. Debating Next-Generation Deep Sequencing

    At ESMO, experts assess the clinical use of genome sequencing

    Vienna—Should oncologists begin using deep genome sequencing in their clinical practice? Next-generation sequencing (NGS) technologies...
  41. Is Genomic Sequencing Ready for Prime Time in Drug Selection?

    Next-generation sequencing (NGS) technologies have come a long way since 1977 when Frederick Sanger developed chain-termination sequencing, but are they ready for prime time in drug selection?
    ...
  42. There is the issue about cell-lines vs fresh...

    There is the issue about cell-lines vs fresh cells. Cell-lines have always played, and continue to play, an important role in drug screening and drug development.

    The problem is that cell-lines do...
  43. Venture Capital Goes Genomic

    Robert A. Nagourney, M.D.

    During the 1960s, 70s and into the 90s, a field of investigation arose that examined buyer’s practices when it came to the consumption of goods and services. Algorithms...
  44. Accuracy and Clinical Utility of In Vitro Cytometric Profiling

    Accuracy and clinical utility of in vitro cytometric profiling to personalize chemotherapy: Preliminary findings of a systematic review and meta-analysis.

    Sub-category: Molecular Diagnostics and...
  45. Targetable genetic alterations detected by next-generation sequencing

    Needle biopsies assay on 33 pretherapy primaries and 17 mBCs. NGS of 3,230 exons in 182 cancer-related genes and 37 introns in 14 genes. 117 "potentially" targetable driver mutations were identified...
  46. Gene Sequencing for Drug Selection?

    Researchers have realized that cancer biology is driven by signaling pathways. Cells speak to each other and the messages they send are interpreted via intracellular pathways known as signal...
  47. Foundation Medicine and the Big Barrier to Cancer Genomic Sequencing

    According to Dr. Eric Topol, Director, Scripps Translational Science Institute, recent studies have highlighted the potential value of whole genome or exome sequencing to precisely guide therapy for...
  48. Frontline Avastin Fails to Boost Glioblastoma Survival in Key Trials

    Adding bevacizumab to frontline radiation and temozolomide therapy for glioblastoma produced disappointing results in a double-blind, placebo-controlled phase III trial.

    Bevacizumab (Avastin)...
  49. As for the quality-of-life and symptom end points...

    As for the quality-of-life and symptom end points of the RTOG 0825 trial, Dr. Tsien said she agrees that the effects of Avastin in reducing vascular permeability and edema might lead to a "pseudo...
  50. No Benefit to Avastin for Newly Diagnosed Glioblastoma?

    A heated debate has again developed over the use of Avastin for the treatment of glioblastoma, this time in the front-line setting in combination with chemotherapy in newly diagnosed patients.
    ...
  51. No Benefit Offered By Avastin For Newly Diagnosed Glioblastoma

    The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline...
  52. Avastin fails to prolong life in glioblastoma brain cancer patients

    [Wow! This is blockbuster news! In one study, patients who were expected to benefit the most from Avastin based on "genetic" testing had the worst survival rates.]

    (AP) - New research raises fresh...
  53. Avastin (bevacizumab) and Sprycel (dasatinib) shows promise in Glioblastomas

    The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and...
  54. Smaller Radiation Fields Can Spare Brain When Treating GBM

    New research from Wake Forest Baptist Medical Center shows that patients suffering from aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain...
  55. Understanding Glioblastoma

    John de Groot, M.D.
    MD Anderson Cancer Center

    Gliomas. These primary brain tumors arise within the brain, but we don't know the cell of origin.

    There are multiple grades of gliomas -- grade...
  56. Treatment Options for Glioblastoma and other Gliomas

    Lawrence Recht, M.D.
    Director of Adult Neuro-Oncology
    Stanford Cancer Institute

    The foundation for glioblastoma treatment includes surgery, radiation and the chemotherapeutic agent,...
  57. Incidence and Risk of CNS Metastases with Adjuvant Herceptin

    Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

    E. M. Olson 1, M. Abdel-Rasoul 1,...
  58. Herceptin (Trastuzumab) for Breast Cancer Linked to CNS Metastases

    During the past decade it has been frequently observed that patients with breast cancer treated with a taxane-containing chemotherapy regimen, either in the adjuvant setting or in the metastatic...
  59. Free-floating DNA from tumor could provide early warning?

    Researchers have been focusing on the development of sensitive assays that allow the specific detection of single tumor cells or small amounts of cell-free tumor DNA in the peripheral blood of cancer...
  60. Circulating Tumor DNA Detects Metastatic Breast Cancer

    Circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) is more effective at monitoring metastatic breast cancer than current biomarkers approved by the US Food and Drug...
  61. Companion Diagnostics for Kadcyla?

    The area of pharmacogenomics was ripe for proprietary tests invented alongside a drug and owned by the drug developer and/or a partner in the diagnostic field.

    HercepTest uses immunohistochemistry...
  62. FDA Approves Two Companion Diagnostics For Kadcyla

    Dako, an Agilent Technologies Company and worldwide provider of cancer diagnostics, announced today it has received approval from the U.S. Food and Drug Administration for the addition of Kadcyla in...
  63. Small steps in treating prostate cancer

    Herman Kattlove, M.D.

    New drugs are beginning to make a dent in the invincibility of metastatic prostate cancer. The basis for these advances began with a professor at my medical school, Charles...
  64. View Post

    Robert A. Nagourney, M.D.

    An interesting paper was published in the January 10 NEJM (Abiraterone in Metastatic Prostate Cancer with Previous Chemotherapy, Ryan et al). The study randomized 1,088...
  65. Abiraterone (Zytiga) in Metastatic Prostate Cancer Without Previous Chemotherapy

    Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D.,...
  66. Abiraterone (Zytiga) in Metastatic Prostate Cancer Without Previous Chemotherapy

    Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy

    N Engl J Med. 2012 Dec 10; CJ Ryan, MR Smith, JS de Bono, et al

    (OncologySTAT) - Abiraterone plus prednisone...
  67. FDA Approves Another Drug For Early Prostate Cancer Use

    According to Dr. Bruce Roth, Professor of Medicine at Washington University School of Medicine, primary hormonal therapy, either by surgical removal of the testicles or the administration of an...
  68. Response to anti-HER2 therapy after treatment with Kadcyla

    I've heard from breast cancer patients who were bumped from the T-DM1 clinical trial because of disease progression, which meant that their cancer was growing despite the drug. Bumped off the trial...
  69. FDA Approves Kadcyla (T-DM1 Anitbody conjugate) for Metastatic HER2 Breast Cancer

    The FDA just approved the new treatment for about 20% of breast cancer patients who have a particular form of the disease that overproduces the protein HER-2.

    The drug now called Kadcyla, combines...
  70. Patient-Specific Biomarker Information to Generate a Treatment Approach

    Cell-lines (as described in the article above) are useful for experimentation in labs as they are always available to researchers as a product and do not require harvesting (acquiring of tissue from...
  71. Patient-Specific Cancer Cell Lines Designed To Predict Chemotherapy Sensitivity

    In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their...
  72. Yet Another Study Agrees: Functional Profiling Provides Insight

    Robert A. Nagourney, M.D.

    It was during the last weeks of December that a particularly interesting article crossed my desk. The study done by a group from Toronto, Canada, is entitled Variable...
  73. Gene Mutations Alone Cannot Explain Drug-Resistant Cancer

    (ChemotherapyAdvisor) - The appearance of new genetic mutations during cancer therapy has long been correlated with drug resistance, treatment failure, and ultimately, relapse. But using single-cell...
  74. Disease depends on surrounding normal cells to spread

    This is the second significant cancer advance out of Toronto hospitals just this month, and the second to home in on the healthy tissues that lie in proximity to tumours.

    In a major breakthrough,...
  75. Cancer cells hide by going dormant

    In a major breakthrough that will change the way cancer is studied and treated in the future, Toronto scientists have discovered a key reason why many tumours may return after chemotherapy.

    In a...
Results 1 to 75 of 174
Page 1 of 3 1 2 3


BTC Inc's Disclaimer and Privacy Policy

The material on this site is for information & support purposes only, and is not a substitute for medical advice provided by a licensed health care provider. Always consult your doctor before trying anything that you find online.